Elinzanetant (original) (raw)
Elinzanetant (developmental code names BAY-3427080 GSK-1144814, NT-814) is an orally active small-molecule neurokinin/tachykinin NK1 receptor and NK3 receptor antagonist which is under development by Bayer, GlaxoSmithKline, and NeRRe Therapeutics for the treatment of hot flashes and "sex hormone disorders". It has been found to relieve hot flashes in postmenopausal women and to dose-dependently suppress luteinizing hormone, estradiol, and progesterone levels in premenopausal women. As of August 2021, elinzanetant is in phase 2 clinical trials for hot flashes and "sex hormone disorders". It was also under development for the treatment of schizophrenia and opioid-related disorders, but development was discontinued for these uses.
| Property | Value |
|---|---|
| dbo:abstract | Elinzanetant (developmental code names BAY-3427080 GSK-1144814, NT-814) is an orally active small-molecule neurokinin/tachykinin NK1 receptor and NK3 receptor antagonist which is under development by Bayer, GlaxoSmithKline, and NeRRe Therapeutics for the treatment of hot flashes and "sex hormone disorders". It has been found to relieve hot flashes in postmenopausal women and to dose-dependently suppress luteinizing hormone, estradiol, and progesterone levels in premenopausal women. As of August 2021, elinzanetant is in phase 2 clinical trials for hot flashes and "sex hormone disorders". It was also under development for the treatment of schizophrenia and opioid-related disorders, but development was discontinued for these uses. (en) |
| dbo:casNumber | 929046-33-3 |
| dbo:fdaUniiCode | NZW2BOW35N |
| dbo:kegg | D12123 |
| dbo:pubchem | 16063568 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Elinzanetant_skeletal.svg?width=300 |
| dbo:wikiPageExternalLink | https://adisinsight.springer.com/drugs/800044912 |
| dbo:wikiPageID | 68647130 (xsd:integer) |
| dbo:wikiPageLength | 4487 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1084238690 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Progesterone dbr:Schizophrenia dbc:NK3_receptor_antagonists dbc:Oxazines dbr:Bayer dbr:List_of_investigational_sex-hormonal_agents dbc:Experimental_drugs dbc:Fluoroarenes dbc:Trifluoromethyl_compounds dbr:Oral_administration dbr:GlaxoSmithKline dbc:Antigonadotropins dbr:Clinical_trial dbr:Hot_flash dbr:Receptor_antagonist dbc:Carboxamides dbr:Estradiol dbc:Pyrazines dbc:Pyridines dbr:Luteinizing_hormone dbr:Phases_of_clinical_research dbr:Premenopausal dbr:Postmenopausal dbr:Opioid-related_disorder dbr:Small-molecule dbr:Neurokinin_receptor dbr:NK1_receptor dbr:NK3_receptor |
| dbp:c | 33 (xsd:integer) |
| dbp:casNumber | 929046 (xsd:integer) |
| dbp:chemspiderid | 17223178 (xsd:integer) |
| dbp:f | 7 (xsd:integer) |
| dbp:h | 35 (xsd:integer) |
| dbp:iupacName | N-[6-[-7--3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-pyridin-3-yl]-2-[3,5-bisphenyl]-N,2-dimethylpropanamide (en) |
| dbp:kegg | D12123 (en) |
| dbp:n | 4 (xsd:integer) |
| dbp:o | 3 (xsd:integer) |
| dbp:pubchem | 16063568 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Oral_administration |
| dbp:smiles | CC1=CC2=CCN4C[C@H]5COCCN5C[C@H]4CO (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | DWRIJNIPBUFCQS-DQEYMECFSA-N (en) |
| dbp:synonyms | BAY-3427080; GSK-1144814; NT-814 (en) |
| dbp:unii | NZW2BOW35N (en) |
| dbp:width | 250 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Nervous-system-drug-stub dbt:Reflist dbt:Short_description dbt:Neurokinin_receptor_modulators |
| dct:subject | dbc:NK3_receptor_antagonists dbc:Oxazines dbc:Experimental_drugs dbc:Fluoroarenes dbc:Trifluoromethyl_compounds dbc:Antigonadotropins dbc:Carboxamides dbc:Pyrazines dbc:Pyridines |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Elinzanetant (developmental code names BAY-3427080 GSK-1144814, NT-814) is an orally active small-molecule neurokinin/tachykinin NK1 receptor and NK3 receptor antagonist which is under development by Bayer, GlaxoSmithKline, and NeRRe Therapeutics for the treatment of hot flashes and "sex hormone disorders". It has been found to relieve hot flashes in postmenopausal women and to dose-dependently suppress luteinizing hormone, estradiol, and progesterone levels in premenopausal women. As of August 2021, elinzanetant is in phase 2 clinical trials for hot flashes and "sex hormone disorders". It was also under development for the treatment of schizophrenia and opioid-related disorders, but development was discontinued for these uses. (en) |
| rdfs:label | Elinzanetant (en) |
| owl:sameAs | wikidata:Elinzanetant https://global.dbpedia.org/id/G6fBh |
| prov:wasDerivedFrom | wikipedia-en:Elinzanetant?oldid=1084238690&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Elinzanetant_skeletal.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Elinzanetant |
| is dbo:wikiPageWikiLink of | dbr:List_of_investigational_sex-hormonal_agents dbr:Tachykinin_receptor_1 dbr:Tachykinin_receptor_3 |
| is foaf:primaryTopic of | wikipedia-en:Elinzanetant |
